The experiences of adults with ADHD in interpersonal relationships and online communities: A qualitative study

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol)

The experiences of adults with ADHD in interpersonal relationships and online communities: A qualitative study

Phase 3 Trial Success: Solriamfetol for the Treatment of Adults With ADHD

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD achieved its primary and key secondary endpoints, demonstrating statistically significant improvements in ADHD symptoms and disease severity compared to placebo.